Study to Evaluate the Safety and Efficacy of Two Adalimumab Dosing Regimens in Subjects With Moderate to Severe Ulcerative Colitis

NCT02065622 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

952

Enrollment

INDUSTRY

Sponsor class

Conditions

Ulcerative Colitis (UC)

Interventions

DRUG: Adalimumab
OTHER: Placebo

Sponsor

AbbVie